Skip to main content

InMed Pharmaceuticals Inc.

INM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001728328

In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 3 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding InMed Pharmaceuticals Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of INM: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders18115−2
Shares1.10M24133.2K−963.6K (−87.9%)
Value$514.5K$0$876.9K+$362.4K (+70.4%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held InMed Pharmaceuticals Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to INM in Q3 2022
InstitutionSharesValue% of portfolio
Sabby Management, LLC15,284$101.0K0.22%
Millennium Management LLC13,922$91.0K0.00%
Bank of America Corp6,770$45.0K0.00%
UBS Group AG5,797$38.0K0.00%
Tower Research Capital LLC (TRC)1,067$7.00K0.00%

Sold out (7)

Institutions that held InMed Pharmaceuticals Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of INM in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Renaissance Technologies LLC49,700$23.0K
Two Sigma Advisers, LP48,281$23.0K
Geode Capital Management, LLC13,905$6.00K
Citadel Advisors LLC12,966$6.00K
Creative Planning10,832$5.00K
Toronto Dominion Bank50$0
Banque Cantonale Vaudoise3$0

Not filed for Q3 2022 yet (1)

Institutions that held InMed Pharmaceuticals Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding INM in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
HC Financial Advisors Inc24$0